Tucatinib in Patients With CRC: Data From MOUNTAINEER-01

Opinion
Video

In the Phase 2 MOUNTAINEER-01 study of patients with HER2-positive metastatic colorectal cancer who were chemo-refractory, the combination of tucatinib and trastuzumab showed an impressive response rate and disease control rate, and median duration of response up to 12 months; Dr. Ahn notes these results compare favorably to prior studies of dual HER2 inhibition, with MOUNTAINEER-01 showing higher response rates.

Recent Videos
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series
4 KOLs are featured in this series.
4 KOLs are featured in this series
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Related Content
A Variety of Treatment Options Are Becoming Available in CRC

A Variety of Treatment Options Are Becoming Available in CRC

ONCOLOGY Staff
December 31st 2023
Article

Kristen K. Ciombor, MD, MSCI, gives an overview of the current treatment landscape for patients with metastatic colorectal cancer.

New treatment updates could help find more patient subtypes to target and treat in the world of CRC.

Multidisciplinary Care and New Treatment Options in CRC

Kristen K. Ciombor, MD, MSCI
November 20th 2023
Podcast

New treatment updates could help find more patient subtypes to target and treat in the world of CRC, according to Kristen K. Ciombor, MD, MSCI.

Cabozantinib plus nivolumab and ipilimumab appears to improve progression-free survival vs cabozantinib alone among patients with metastatic soft-tissue sarcoma in a phase 2 trial.

Cabozantinib Combo Yields Disease Control in Metastatic Soft Tissue Sarcoma

Brielle Benyon
June 5th 2023
Article

Cabozantinib plus nivolumab and ipilimumab appears to improve progression-free survival vs cabozantinib alone among patients with metastatic soft-tissue sarcoma in a phase 2 trial.

Collaboration in kidney cancer palliative care and integrative medicine programs underscores the current development of University Hospitals’ integrative oncology wing.

Expert Outlines Collaborative Integrative Oncology Plans in Kidney Cancer

Santosh Rao, MD
April 10th 2023
Article

Collaboration in kidney cancer palliative care and integrative medicine programs underscores the current development of University Hospitals’ integrative oncology wing.